• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

ArQule

edit

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company’s product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

Recent Milestones

edit

• 
  ArQule — ArQule license deal with Daiichi could land $265M (11/10/11)
  Posted 11/10/11 at 8:45pm via masshightech.com
• 
  ArQule — has closed a public offering of stock, bringing in $46.5 million after expenses, which was $6 million more than the company expected (1/26/11)
  Posted 1/26/11 at 6:28am via masshightech.com
• 
  ArQule — Arqule clears $6M more than expected in stock sale (1/26/11)
  Posted 1/27/11 at 1:03am via masshightech.com
• 
  ArQule — ArQule plans $40.5M stock offering (1/20/11)
  Posted 1/21/11 at 8:12pm via masshightech.com
• 
  Went public with stock symbol NASDAQ:ARQL.
  Posted 1/21/11 at 8:11pm
• 
  ArQule added Paolo Pucci as CEO.
  Posted 1/21/11 at 8:10pm
• 
  ArQule added Peter S. Lawrence as President and CEO.
  Posted 1/21/11 at 8:10pm

Videos

Screenshots

edit

Stock Price

Sources

ArQule plans $40.5M stock offering (masshightech.com) [edit]
Arqule clears $6M more than expected in stock sale (masshightech.com) [edit]
Arqule clears $6M more than expected in stock sale (masshightech.com) [edit]
ArQule license deal with Daiichi could land $265M (masshightech.com) [edit]